- Home
- PRAX vs PFSI Comparison
PRAX vs PFSI Comparison
Compare PRAX & PFSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRAX | PFSI |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.8B |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | PRAX | PFSI |
|---|---|---|
| Price | $278.87 | $146.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $373.79 | $148.38 |
| AVG Volume (30 Days) | ★ 580.2K | 307.2K |
| Earning Date | 02-27-2026 | 01-29-2026 |
| Dividend Yield | N/A | ★ 0.82% |
| EPS Growth | N/A | ★ 191.00 |
| EPS | N/A | ★ 9.30 |
| Revenue | $7,463,000.00 | ★ $2,723,457,000.00 |
| Revenue This Year | N/A | $6.22 |
| Revenue Next Year | $12,467.71 | $28.90 |
| P/E Ratio | ★ N/A | $15.72 |
| Revenue Growth | ★ 364.98 | 21.25 |
| 52 Week Low | $26.70 | $85.74 |
| 52 Week High | $317.72 | $146.68 |
Technical Indicators
Market Signals| Indicator | PRAX | PFSI |
|---|---|---|
| Relative Strength Index (RSI) | 55.41 | 78.93 |
| Support Level | $268.78 | $129.37 |
| Resistance Level | $305.21 | $134.91 |
| Average True Range (ATR) | 15.32 | 3.38 |
| MACD | -3.91 | 1.22 |
| Stochastic Oscillator | 20.68 | 90.16 |
Price Performance
Historical ComparisonAbout PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About PFSI PennyMac Financial Services Inc.
PennyMac Financial Services Inc is a specialty financial services firm with a comprehensive mortgage platform and integrated business focused on the production and servicing of U.S. residential mortgage loans. The company operates through two segments: production and servicing. The production segment performs loan origination, acquisition and sale activities. The servicing segment performs loan servicing for newly originated loans.